FAQ Home

Find Answers


How is the KRASG13D mutant-A375 Isogenic cells (ATCC® CRL-1619IG-1 ™) validated?

This line has been tested in parallel with the A-375 [A375] (ATCC® CRL-1619 ™) parental line at the genomic, transcript and cellular levels as well as assayed for the desired phenotypic functional activity resembling the intended genotypic G13D heterozygous knock-in mutation.  We observed significant levels of drug resistance to both BRAF-specific inhibitors, Dabrafenib and Vemurafenib treatment. 

Date Created09/28/2017 03:42 PM
Date Updated09/28/2017 03:43 PM

Most Popular Answers

  1. Huh7 cell line
  2. ATCC HUVEC lines
  3. Passage number vs. population doubling level (PDL)
  4. U-373 MG (ATCC® HTB-17)
  5. Converting TCID[50] to plaque forming units (PFU)